ARTBIO is a clinical-stage radiopharmaceutical company that develops new alpha radioligand therapies (ARTs). ARTBIO's approach uses tumor-specific targets and the best alpha-precursor isotope (Pb212) to develop safe and effective therapeutics.

<p>ARTBIO is a clinical-stage radiopharmaceutical company that develops new alpha radioligand therapies (ARTs). ARTBIO&#39;s approach uses tumor-specific targets and the best alpha-precursor isotope (Pb212) to develop safe and effective therapeutics. ARTBIO is working with SpectronRx to develop a new prostate cancer therapy called AB001.</p>


ARTBIO

Office Manager / Lab Supervisor

Associate Director, Radiopharmaceutical Development

Clinical and Preclinical Quality Director

Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities - Business Wire

 ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer 

☢️ New job alert!

ARTBIO is looking for a Clinical Trial Finance Associate. This role will support the Clinical Operations team and can be in London or Boston. It's a great opportunity to support a biotech that is innovating alpha radioligand therapies for patient-centric cancer care!

Apply here or reach out to me directly. 

#hiring #financeassociate #clinicaloperations #hiringinbiotech #clinicaltrialbudgeting #newjob #RLT


Artbio raises $90M as radiopharma field finds its footing - Endpoints News

SpectronRx and ARTBIO Join Forces to Develop and Manufacture Clinical Supply of Novel Alpha Radioligand Therapy AB001 for Indiana and Surrounding States - Business Wire

Technical Operations & ManufacturingRadioprotection OfficerOslo

Nucleus RadioPharma makes Artbio’s radiopharma assets; Minaris manufactures bluebird’s Lyfgenia - Endpoints News

Artbio launches for alpha-emitting radiopharmaceuticals to treat cancer - Chemical & Engineering News

Artbio and 3B Pharmaceuticals to advance α-radioligand therapy for solid tumors - BioWorld Online

 Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates 

 ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors 

Thor Medical and ARTBIO sign strategic long-term supply agreement for Thorium-228 - NTB Kommunikasjon

FogPharma, ARTBIO Partner To Develop Helicon-Enabled ARTs (HEARTs) - Contract Pharma

 The Week's 10 Biggest Funding Rounds: X-Energy And ... 


                New Series: Leading with Lead
              

ARTBIO, PharmaLogic Enter Manufacturing And Supply Pact - Contract Pharma

Research & DevelopmentResearch Associate II/Senior Research Associate, BiologyCambridge, MA

ARTBIO, PharmaLogic Enter Manufacturing and Supply Pact - Contract Pharma

Excited about alpha radioligand therapies and peptide science? ARTBIO is hiring!

#radioligandtherapy #peptidechemistry #peptides #SAR #drugdevelopment

 Artbio brings in $90M for radioactive molecules that target cancer 

 Artbio raises $90M as radiopharma field finds its footing 

 GSK, Novartis, among winners at LSX Awards - BioProcess ... 

 SpectronRx and ARTBIO Join Forces to Develop and Manufacture Clinical Supply of Novel Alpha Radioligand Therapy ... 

Artbio brings in $90M for radioactive molecules that target cancer - The Business Journals

Our very own Victor Paulus was featured in the latest episode of “A Dose of Reality” podcast. It’s talented and driven colleagues like Victor that help build ARTBIO and enable us to bring life-changing and innovative #alpha #radioligand #therapies to patients in need.
 
Check out the episode in the link below to learn why ARTBIO is a special place for Victor, but also to learn from his experiences in regulatory, drug development the exciting space of #radiopharmaceuticals.

 Nucleus RadioPharma unveils manufacturing pact with ARTBIO 

 AlphaGen And ArtBio Form China-US Radioligand Partnership 

FogPharma, ARTBIO Partner to Develop Helicon-Enabled ARTs (HEARTs) - Contract Pharma

SpectronRx, ARTBIO Partner on Alpha Radioligand Therapy - Contract Pharma


              Emanuele Ostuni - CEO, ARTBIO
            

CDMO Nucleus RadioPharma links up with ARTBIO to help produce prostate cancer candidate for clinical trials - FiercePharma


              Radiopharmaceutical Strategies Begin To Take Shape As Field Rolls Into 2025
            

 Artbio raises $23M to advance lead-based radioligand therapies for prostate cancer 

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies - PR Newswire


                New NIST Standard Helps Deliver the Right Dosage of Cancer-Fighting Drugs
              

ARTBIO Announces Appointment of Nicole Hadas as Chief Legal OfficerARTBIO | January 21, 2025

ARTBIO and Oslo University Hospital Announce Collaboration to Advance the Research and Development of Alpha Radioligand TherapiesARTBIO, Oslo University Hospital | June 5, 2024

 ARTBIO: $90 Million Secured To Develop New Class Of Alpha Radioligand Therapies 

The ARTBIO team is excited to be attending several upcoming events in the coming weeks, including the William Blair Conference, the ICPO Foundation-International Centers for Precision Oncology Theranostics Summit, and the 2024 Jefferies London Healthcare Conference!

ARTBIO Chief Scientific Officer Nick Pullen will be speaking at the ICPO Summit with a first disclosure of pre-clinical data underwriting the superiority of alpha emission in a bone metastasis Prostate Cancer model, as well as clinical data from a Ph0 evaluation of AB001.

ARTBIO Chief Executive Officer Emanuele Ostuni will be joining Andy Hsieh for a fireside chat as part of the William Blair’s Innovator Series: Radiopharmaceuticals, discussing ARTBIO’s vision for Pb212-based alpha radioligand therapies and the progress the company has made since its inception.

We look forward to insightful discussions and sharing the latest updates about our approach to #Alpha #Radioligand #Therapies (#ART). Find out more about our unique approach at https://artbio.com/

#WilliamBlair #JefferiesHealthcare #RadioligandTherapy #Radiopharmaceuticals #Biotech #NuclearMedicine

Research & DevelopmentPrincipal Scientist/Associate Director, Peptide ChemistryCambridge, MA

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid TumorsARTBIO, 3B Pharmaceuticals | November 14, 2024

Thor Medical invitation to capital markets update | Thor Medical ASA - NTB Kommunikasjon

ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New York and Surrounding States - PR Newswire

 Rain in Gaza: Displaced Palestinians Face Heightened ... 

ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials - Business Wire

FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer - Business Wire

Research & DevelopmentAnimal TechnicianOslo

 Fogpharma and Artbio collaborate to create new class of α-radioligand therapeutics for solid tumors 

ARTBIO is attending #bioequityeurope in Bruges, Belgium.
Our CEO Emanuele Ostuni will join a panel to discuss “Radiopharma: A Complex Modality Goes Global”. 
The panel will be moderated by Karen Tkach Tuzman, Ph.D., Director of Biopharma Intelligence and Head of Discovery and Preclinical Research, BioCentury Inc. and will feature radiopharma industry leaders:
 
Philipp Bräuer, PhD., VP, EQT Life Sciences
Germo Gericke, MD., Chief Medical Officer, Ariceum Therapeutics
Sven Van den Berghe, PhD., CEO, PANTERA
Duncan Young, PhD., Executive Director, Search & Evaluation, Oncology at AstraZeneca
 
Date/Time: May 13th from 11:15am – 12pm CET
Location: ⁠Bruges Meeting & Convention Centre (BMCC)
 
#nuclearmedicine #biotech #radiopharmaceuticals #RadioligandTherapy #LifeSciences #CancerCare 

 Nucleus RadioPharma makes Artbio’s radiopharma assets; Minaris manufactures bluebird’s Lyfgenia 

ClinicalSenior Medical Director, Clinical DevelopmentCambridge, MA

Our ARTBIO team is headed to New Orleans to attend the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting!  
 
Interested in learning more about the future of radiopharmaceuticals? Connect with our experts onsite to hear how ARTBIO is redefining alpha therapies with AlphaDirect and 212Pb! 

Amaury Guillou, PhD Jonathan Goodwin Marion Masitsa Malenge Phil Ruis Jenna M. Sullivan Conrad Wüller
 
#NuclearMedicine #Biotech #Radiopharmaceuticals #RadioligandTherapy #LifeSciences #CancerCare

 RLS expands by offering radiopharmaceutical contract ... 

 “Survivor 45” exclusive deleted scene flashes back to day 1 of ... 

J&J’s Margaret Yu named Artbio CMO - The Pharma Letter

Radiopharma startup Artbio raises $90M in sign of field’s momentum - BioPharma Dive

ARTBIO and SpectronRx Enter a Collaboration to Manufacture Key Components of ARTBIO's AlphaDirect™ Technology - PR Newswire

ARTBIO divulges plans for proprietary isotope manufacturing technology - Pharmaceutical Technology

ARTBIO Expands Radiopharmaceutical R&D Capabilities with Move to Oslo Science ParkARTBIO, Oslo Science Park | May 16, 2025

Norwegian biotech startup nabs $23M seed to develop radiopharmaceuticals for prostate cancer - ArcticStartup - ArcticStartup

Lilly picks new head of diabetes, obesity unit—Chutes & ...


                Breakthrough mini-protein revolutionizes how we treat cancer
              

Fierce Biotech Fundraising Tracker '23

 Women played a leading role in the pandemic-fueled boom in ... 

Swiss Biotech Day is here! ARTBIO is participating and supporting the Swiss biotech ecosystem with two important contributions by our CEO Emanuele Ostuni:
 
Unleashing the power of Alpha Radioligand Therapy (ART) tomorrow at 12:45
 
Radio Therapy Panel sponsored by Molecular Partners tomorrow at 15.00 - hosted by Philippe Legenne, with  Melpomeni Fani, University Hospital Basel, Sibylle Jennings, Novartis and Arnaud Lesegretain, Orano Med. 

We look forward to the insights and continued progress for the field of #alpha #radioligand #therapy

#nuclearmedicine #radiopharmaceuticals #swissbiotechday

Ivana Galetic Conrad Wüller Swiss Biotech Association


              ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors
            

ARTBIO Announces Appointment of Margaret Yu, M.D., as Chief Medical OfficerARTBIO | January 9, 2025

 Updated: Radiopharmaceuticals Market Predicted to Grow ... 

ARTBIO secures $90m to advance ART pipeline - Pharmaceutical Technology


                Leading with Lead #5
              

ARTBIO inks exclusive deal with 3BP to grow radioligand pipeline - The Pharma Letter

We are delighted to announce that ARTBIO has entered into a master supply agreement with Thor Medical ASA. Thor Medical will supply #thorium (Th-228) to ARTBIO for the manufacturing of Pb212 through our proprietary AlphaDirect technology to support the development of our pipeline of novel #Alpha #Radioligand #Therapies. Learn more: https://shorturl.at/l9GXl 

Thor Medical is pioneering methods to recover Th228 from existing material stockpiles rather than manufacturing it by irradiating other materials. We look forward to working closely with them in our Oslo laboratories, not far away from their production site.

#NuclearMedicine #RadioligandTherapy #Radiopharmaceuticals #Biotech #ProstateCancer #ARTs

Week In Review: AlphaGen And ArtBio Form China-U.S. Radioligand Partnership - Seeking Alpha

ARTBIO has a new home for bold ideas and breakthrough science. We have relocated our European research labs to Forskningsparken - Oslo Science Park, opening the door to expanded research #collaborations, new academic #partnerships, and advancing cutting-edge, radiation-enabled R&D and #technology development.
 
 
This move marks more than a change in address. We’re building a space designed to inspire scientific excellence in radiopharmaceutical, preclinical biology research and generate technology advancements for novel cancer treatments. Our new lab brings us even closer to leading academic institutions, research partners, and hospital systems, enabling deeper collaboration and faster progress for the patients we serve.

To our new partners, colleagues, and #community: Thank you for being part of this journey. We can’t wait to get started. Read the press release here: https://lnkd.in/dpagWf4e 
 
#nuclearmedicine #biotech #radiopharmaceuticals #RadioligandTherapy #LifeSciences #CancerCare

Cody AS Thor Medical ASA Jasper C. Kurth Oncoinvent ASA Oslo Cancer Cluster Bjørn Erik Reinseth RADFORSK Anders Tuv Ole Kristian Hjelstuen Leif Rune Skymoen The Life Science Cluster Hanne Mette Kristensen Magnus Skoglund Larsen Hans-Peter Daae

Check out this job at ARTBIO: CDMO Tech Transfer Lead

 ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New ... 


                Part 2: Leading with Lead
              


                Therapeutic evaluation of [212Pb]Pb-AB001 and [177Lu]Lu-PSMA-617 in a mouse model of disseminated prostate cancer - European Journal of Nuclear Medicine and Molecular Imaging
              

ARTBIO will attend the 4th annual ICPO Foundation-International Centers for Precision Oncology Forum in Garching, Germany, and our VP Clinical Development Vicki Jardine is presenting Pb212 clinical opportunities for targeted #alpha #radioligand #therapies.
 
Be sure to check out her session on May 16th at 15:30 CET.
 
#nuclearmedicine #biotech #radiopharmaceuticals #RadioligandTherapy #LifeSciences #CancerCare

The group I'm in at ARTBIO is growing! We are looking for a biochemist/biophysicist with some plate based assay experience (SPR or ITC experience are a plus)! Reach out if you're interested or know someone that might be a good fit! 

 https://lnkd.in/ePUZqZVk 

🏃♀️ 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗺𝗼𝘁𝗶𝗼𝗻! 🏃♂️

This past Saturday, NucliThera laced up for 𝗛𝗼𝗹𝗺𝗲𝗻𝗸𝗼𝗹𝗹𝘀𝘁𝗮𝗳𝗲𝘁𝘁𝗲𝗻 - one of the world's largest relay races - joining forces with our colleagues from ARTBIO and Oncoinvent ASA to form a 𝘂𝗻𝗶𝘁𝗲𝗱 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗿𝗮𝗱𝗶𝗮𝘁𝗶𝗼𝗻 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘁𝗲𝗮𝗺!

As a small and growing company, collaboration is at the heart of what we do — not just in science, but in spirit. We're proud that Anna Maria Sæther represented NucliThera on the course, embodying the energy and determination we bring to our mission: delivering new and effective treatments to people living with cancer.

This year also celebrates 50 years of female participation in the event — a powerful reminder of the progress that can be made when barriers are broken and inclusion is prioritized.

👏 Huge thanks to everyone who ran, cheered, and made it a day to remember. It was a celebration of science, health, and shared determination — on the track and beyond 💪

🎉 Special thanks to Elisa Napoli, PhD, whose initiative and organization turned this idea into an unforgettable race-day collaboration.

#Holmenkollstafetten #RadioligandTherapy #NucliThera #CancerResearch #WomenInScience #Collaboration

Tanja Aarvak, Elise Damlien, Roxanne Wouters, Kim Lindland, Amaury Guillou, PhD, Nisarg Soni, Ph.D, Wouter van Eijmeren, Ruth Gong Li, Richard Crispin, Célia Seillier, PhD

ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential - PR Newswire

Excited to be heading to Bergen soon for this year's LSX Nordic Congress (20-21 May) to (re)connect and exchange with peers, academia and investors. Especially looking forward to our panel discussion on the evolving world of #radiopharmaceuticals.

Oystein Soug Jutta Heix Lars Mørland Knudsen Frans Suurs ARTBIO Oslo Cancer Cluster Oncoinvent ASA p53 Bayer

#nuclearmedicine #radioligandtherapy

Deals Report: J&J acquires Proteologix, Fog-ARTbio to develop radiotherapies - BioCentury

SpectronRx, ARTBIO Partner On Alpha Radioligand Therapy - Contract Pharma

 Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities 

Artbio emerges with $23M to make radioligand therapies for prostate cancer, with field still in 'early days' - Endpoints News

Finance & AccountingClinical Trial Finance AssociateLondon

The European Association of Nuclear Medicine (EANM) Annual Congress kicks off this Saturday and we’re thrilled to be attending! 

Join us as we explore the latest advancements in #NuclearMedicine, share insights with industry leaders, and connect with fellow innovators. Together, we can shape the future of patient care and drive meaningful change in the field. Stay tuned for updates from the event!

#EANM24 #RadioligandTherapy #Radiopharmaceuticals #Biotech

Emanuele Ostuni | Conrad Wüller | ✪ Philippe Dasse ✪ ☤ | Daniel Rossetto | Phil Ruis | Vicki Jardine | Ivana Galetic | Mohana Suppiah-Coll | Tanja Aarvak | Elisa Fiorito, Ph.D. | Vilde Yuli Stenberg | Joshua Needham-Clark | Rosa Greasley | Jordi Vall-llossera


                Radioligand Therapy: A New Cancer Treatment Paradigm?
              

Investors pour $90M onto ARTBIO's palette less than 6 months after launching - Fierce Biotech

The ARTBIO team is excited to attend both the Hanson Wade Group’s 6th Annual Targeted Radiopharmaceuticals Summit Europe and the 36th Annual Piper Sandler Healthcare Conference from December 3-5!

At the Targeted Radiopharmaceuticals Summit Europe in Amsterdam, we’ll connect with industry leaders to exchange insights, explore innovative solutions, and contribute to discussions advancing radiopharmaceutical therapies. Our colleagues Vicki Jardine and Daniel Rossetto will share ARTBIO’s vision for Pb212-based #Alpha #Radioligand #Therapies (#ART).

Emanuele Ostuni is looking forward to in-depth discussions on emerging trends, connecting with experts, and gaining fresh strategies at the Piper Sandler Healthcare Conference. We hope to see you there! 

Learn more about our innovative methods and recent partnerships at https://artbio.com/

#RadioligandTherapy #Radiopharmaceuticals #Biotech #NuclearMedicine


                Part 3: Leading with Lead
              

ARTBIO team members Emanuele Ostuni, Nick Pullen, and Conrad Wüller will attend the J.P. Morgan 43rd Annual Healthcare Conference in San Francisco next month! 

We're eager to connect with industry leaders, share our progress, and explore partnerships to advance #Alpha #Radioligand #Therapies (#ART) as a transformative treatment for #Cancer.

We're also honored to have the opportunity to present our company on Thursday, January 16, at 9:00 AM as part of the conference agenda.

#JPM25 #Radiopharmaceuticals #Biotech #NuclearMedicine


At ARTBIO, we are full of pride. Not only because of our patient-centric programs, but because we value our #employees and #partners who contribute diverse viewpoints and opinions. Before this #Pride #Month comes to a close, ARTBIO celebrates all individuals who bring their authentic self to work each and every day. ARTBIO will always be a place to call home regardless of your lifestyle. If you’re interested in learning more about our company culture and exploring current opportunities, visit www.artbio.com. 

#radiopharmaceuticals #nuclearmedicine #alpha #radioligand #therapy

ARTBIO Home Page

FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of CancerARTBIO, FogPharma | May 14, 2024

ARTBIO, Nucleus RadioPharma Enter Manufacturing & Supply Pact - Contract Pharma

 AlphaGen and ArtBio Form China-US Partnership for Radioligand Therapies 

FogPharma, Artbio join forces to design a different radiopharma drug - BioPharma Dive

ARTBIO

Business:

Drug notes:

About: